Photocure fundamentale forhold (PHO)

rockpus · september 20, 2019, 10:41am

Når vil vi se arvtakerne etter High Seas AS sin andel?

sulzrox · oktober 1, 2019, 9:34am

Når eit sykehus kjøper Cysview for dei første gangene, er det da vanlig med rabatt?

@Rodjer Kanskje du veit svare på dette eventuelt kan spørre Photocure ein gang du prata med dei?

På Q rapporten skriv dei prisøkning og eg tenker det har noe med rabatter?

pdx · oktober 1, 2019, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Rodjer (775 likes)

@Savepig (500 likes)

@Snoeffelen (293 likes)

Resten av topp 10:

@Londonmannen (243 likes)
@Mr.Oncoinvest (158 likes)
@solvoll (143 likes)
@sjog (126 likes)
@ufo (113 likes)
@togulle (110 likes)
@tekdude (96 likes)

Gratulerer!

Savepig · oktober 1, 2019, 7:39pm

Savepig · oktober 25, 2019, 1:13pm

Photocure presentert poster:

Antitumor effect and induced systemic immune effects of HAL used in PDD doses in an orthotopic model of rat bladder cancer

TekBot · oktober 28, 2019, 7:19am

Photocure: New data from Hexvix® trials presented at the BLADDR 2019 congress

Oslo, Norway, October 28th, 2019: today Photocure ASA announced highlights from
the BLADDR 2019 congress, October 25-26 in Paris, France. The BLADDR congress is
solely focused on bladder cancer and attracts bladder cancer experts from all
…

Vis børsmeldingen

over the world.

Data from two Hexvix studies were presented at the congress:

Antitumor effect and induced systemic immune effects of HAL and blue light in an
orthotopic model of rat bladder cancer, presented by Kari Myren, MD, Head of
Global Medical Affairs and Clinical Development, Photocure, Oslo, Norway. These
are the first published data from a pre-clinical study investigating potential
treatment effects of Blue Light Cystoscopy (BLCT) with Hexvix. The results of
the study indicate for the first time that a treatment effect could be related
to immunogenic cell death responses and anti-tumor immune cell activation.

Here is a link to the abstract: https://bit.ly/2kKnE7Y

The second abstract was based on results from the Nordic registry study with
Hexvix and flexible cystoscopes in the office setting: Malignant urinary
cytology of unknown origin - blue light flexible cystoscopy with
Hexaminolevulinate (HAL) at the outpatient clinic may be a valuable diagnostic
and therapeutic tool, presented by Marie Andersson, Department of Urology,
Helsingborg hospital, Sweden.

The author concluded that flexible BLC with flexible cystoscopes in the
outpatient clinic may in a simple way solve many unclear cases with malign or
suspicious urinary cytology. The procedure is well tolerated and generally
preferred by patients over a procedure in the operating room under general
anesthesia.

Here is a link to the abstract: https://bit.ly/2kzsRQf

“It is encouraging to see new data on Hexvix being presented at an international
bladder cancer expert congress, clearly showing the immense potential Hexvix
has. The flex study demonstrating how using Hexvix in the outpatient
clinic/office can solve challenging cases for the benefit of patients and
providers, and the first pre-clinical data indicating that Blue Light cystoscopy
with Hexvix might have a treatment effect. These early data are very exciting,
and we look forward to exploring this further”, says Dan Schneider, President
and CEO of Photocure.

About Bladder Cancer

Bladder cancer ranks as the ninth most common cancer worldwide with 430 000 new
cases and more than 165 000 deaths annually. Approx. 75% of all bladder cancer
cases occur in men[1]. It has a high recurrence rate with an average of 61% in
year one and 78% over five years[2]. Bladder cancer has the highest lifetime
treatment costs per patient of all cancers[3].

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. MIBC is when the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3 and T4, are more likely to spread and are harder to treat[4].

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix[®]/Cysview[®] is a drug that is selectively taken up by tumor cells in
the bladder making them glow bright pink during Blue Light Cystoscopy (BLC[TM]).
BLCT with Hexvix[®] /Cysview[®] improves the detection of tumors and leads to
more complete resection, fewer residual tumors and better management decisions.

Cysview[®] is the tradename in the US and Canada, Hexvix[®] is the tradename in
all other markets. Photocure is commercializing Cysview[®] / Hexvix[®] directly
in the US and the Nordic region and has strategic partnerships for the
commercialization of Hexvix[® ]/ Cysview[®] in Europe, Canada, Australia and New
Zealand. Please refer to https://bit.ly/2wzqSQQ for further information on our
commercial partners.

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

References

Globocan. Incidence/mortality by population. Available
at: http://globocan.iarc.fr/Default.aspx

Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al.
EAU Guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS). Eur Urol.
2016 Guidelines Edition:1-40.

Sievert KD et al. World J Urol 2009;27:295-300

Bladder Cancer. American Cancer Society.
https://www.cancer.org/cancer/bladder-cancer.html

For more information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Tel: + 1-609 759-6515
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, which makes
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

Kilde

TekBot · oktober 30, 2019, 9:07am

Photocure ASA: Invitation to third quarter 2019 results presentation and webcast

Photocure will present its third quarter report on Thursday 7 November 2019 at
Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET).

…

Vis børsmeldingen

Representatives from the company will be Daniel Schneider, CEO and Erik Dahl,
CFO. The presentation will be held in English.

The quarterly report and presentation will be published at 07:00 CET and will be
publicly available at www.photocure.com. It will be possible to follow the
presentation through https://webtv.hegnar.no/presentation.php?webcastId=98164404

A light snack will be served from 08:00 (CET). The presentation is scheduled to
conclude at 09:15 (CET).

Please register your attendance to the presentations at Photocure by Wednesday 6
November 14:00 CET. Contact person: Tolv Hillestad (e-mail: th@photocure.no /
phone +47 22 06 22 10).

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

pdx · november 1, 2019, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Rodjer (923 likes)

@Savepig (423 likes)

@Snoeffelen (193 likes)

Resten av topp 10:

@Londonmannen (172 likes)
@solvoll (159 likes)
@Mr.Oncoinvest (118 likes)
@myk (116 likes)
@RakiRebSnem (101 likes)
@togulle (97 likes)
@Hayen (97 likes)

Gratulerer!

Savepig · november 4, 2019, 1:40pm

Hvis noen frykter at det ikke er hold i Asieris sin satsing på Cevira:

http://www.asieris.cn/index.php/content/176

Durable · november 4, 2019, 4:52pm

Cevira har meget gode muligheter for å bli en blockbuster. Milliarder av DOLLAR i omsetning. $$$!

Jeg tror mange ikke helt har tatt inn over seg hvor mye dette ekstra «benet å stå på» de-risker hele PhotoCure-caset.

Dersom satsningen på Cysview og blærekreft mot formodning skulle mislykkes, kan Cevira likevel gjøre en investering i PhotoCure-aksjer til en virkelig «gullgruve».

Savepig · november 4, 2019, 4:54pm

Nei akkurat nå prises Cevira mer eller mindre til null.

Durable · november 4, 2019, 9:24pm

Folk forstår vel ikke Cevira, av en eller annen grunn.

Jeg vil påstå, at dersom Cevira hadde blitt skilt ut i et eget selskap, så burde det alene ha forsvart tilsvarende dagens kurs.
Vi snakker faktisk om oppstart i fase 3, med blockbuster-potensiale og meget gode kliniske data i tidligere faser.

Og forhåpentligvis raskere vei til markedet, fordi ting gjøres smidigere og mindre byråkratisk i Kina enn i USA og Europa.

Savepig · november 4, 2019, 9:27pm

Men dette er også standard i biotech, er kun lead product som blir priset på noen fornuftig måte.

TekBot · november 5, 2019, 7:22pm

Photocure: Cysview® reimbursement further improved from January 2020

Oslo, Norway, November 6,[ ]2019 Photocure ASA., (OSE: PHO), The United States
Centers for Medicare and Medicaid Services (CMS) has released its Final Rule
maintaining the reimbursement code (A Code) for Cysview when used in hospital
outpatient and other sites of care and improved the complexity adjustment
codes.

This will result in additional reimbursement of $92 for certain Blue
Light Cystoscopy (BLCT) procedures when used in hospital outpatient departments
effective January 1st, 2020.

Link for access to the Rule: https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-24138.pdf

In addition, CMS confirmed that the complexity adjustment will be available for
procedures billed under 52204, 52214, and 52224 (52214 being new for 2020), if
also billed with the A9589 code for the drug and the C9738 code for the
complexity adjustment.

The increased reimbursement due to the complexity adjustment will be $1,247 ($1,187 in 2019).
This will result in an increase in reimbursement of payment for Blue Light Cystoscopy procedures when used in hospital outpatient department under the complexity adjustment conditions
applicable to the three procedures in 2020 from standard white light at $1,771 (for APC 5373) to $3,018 with Cysview (for APC 5374).

"The effectiveness and benefits of using Blue Light Cystoscopy (BLCT) with
Cysview for improved detection and management of bladder cancer are widely
recognized. We are pleased that CMS has implemented an additional complexity
adjustment code for Cysview and improved reimbursement compared to 2019.

We, along with many stakeholders in the Bladder Cancer Community,
(including the Large Urology Group Practice Association (LUGPA), American Urological
Association (AUA), the patient advocacy group Bladder Cancer Advocacy Network
(BCAN), and individual Urologists and Patients),

will continue to work to further increase access for all patients regardless of the site of care to this
leading-edge technology for the management of bladder cancer," commented Dan
Schneider, President and Chief Executive Officer of Photocure ASA.

CMS final rule expands complexity adjustment for Hospital Outpatient from two to
three procedure codes and increases the reimbursement due to the complexity
adjustment for these procedures by $92 compared to 2019.
…

Vis børsmeldingen

Oslo, Norway, November 6,[ ]2019 Photocure ASA., (OSE: PHO), The United States
Centers for Medicare and Medicaid Services (CMS) has released its Final Rule
maintaining the reimbursement code (A Code) for Cysview when used in hospital
outpatient and other sites of care and improved the complexity adjustment
codes. This will result in additional reimbursement of $92 for certain Blue
Light Cystoscopy (BLCT) procedures when used in hospital outpatient departments
effective January 1st, 2020.

Link for access to the Rule: https://s3.amazonaws.com/public
-inspection.federalregister.gov/2019-24138.pdf

In addition, CMS confirmed that the complexity adjustment will be available for
procedures billed under 52204, 52214, and 52224 (52214 being new for 2020), if
also billed with the A9589 code for the drug and the C9738 code for the
complexity adjustment. The increased reimbursement due to the complexity
adjustment will be $1,247 ($1,187 in 2019). This will result in an increase in
reimbursement of payment for Blue Light Cystoscopy procedures when used in
hospital outpatient department under the complexity adjustment conditions
applicable to the three procedures in 2020 from standard white light at $1,771
(for APC 5373) to $3,018 with Cysview (for APC 5374).

“The effectiveness and benefits of using Blue Light Cystoscopy (BLCT) with
Cysview for improved detection and management of bladder cancer are widely
recognized. We are pleased that CMS has implemented an additional complexity
adjustment code for Cysview and improved reimbursement compared to 2019. We,
along with many stakeholders in the Bladder Cancer Community, (including the
Large Urology Group Practice Association (LUGPA), American Urological
Association (AUA), the patient advocacy group Bladder Cancer Advocacy Network
(BCAN), and individual Urologists and Patients), will continue to work to
further increase access for all patients regardless of the site of care to this
leading-edge technology for the management of bladder cancer,” commented Dan
Schneider, President and Chief Executive Officer of Photocure ASA.

About Bladder Cancer

Bladder cancer ranks as the ninth most common cancer worldwide with 430 000 new
cases and more than 165 000 deaths annually. Approx. 75% of all bladder cancer
cases occur in men[1]. It has a high recurrence rate with an average of 61% in
year one and 78% over five years[2]. Bladder cancer has the highest lifetime
treatment costs per patient of all cancers[3].

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. MIBC is when the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3 and T4, are more likely to spread and are harder to treat[4].

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix[®]/Cysview[®] is a drug that is selectively taken up by tumor cells in
the bladder making them glow bright pink during Blue Light Cystoscopy (BLC[TM]).
BLCT with Hexvix[®] /Cysview[®] improves the detection of tumors and leads to
more complete resection, fewer residual tumors and better management decisions.

Cysview[®] is the tradename in the US and Canada, Hexvix[®] is the tradename in
all other markets. Photocure is commercializing Cysview[®] / Hexvix[®] directly
in the US and the Nordic region and has strategic partnerships for the
commercialization of Hexvix[® ]/ Cysview[®] in Europe, Canada, Australia and New
Zealand. Please refer to https://bit.ly/2wzqSQQ for further information on our
commercial partners.

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

References

Globocan. Incidence/mortality by population. Available
at: http://globocan.iarc.fr/Default.aspx

Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al.
EAU Guidelines on

non-muscle-invasive bladder cancer (Ta, T1 and CIS). Eur Urol. 2016
Guidelines Edition:1-40.

Sievert KD et al. World J Urol 2009;27:295-300

Bladder Cancer. American Cancer Society.
https://www.cancer.org/cancer/bladder-cancer.html

For more information, please contact:

Dan Schneider

President and CEO
Photocure ASA
Tel: + 1-609 759-6515
Email: ds@photocure.com

Erik Dahl

CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, which makes
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

Kilde

Savepig · november 5, 2019, 5:00pm

Må være ærlig og si jeg synes disse reglene er rimelig greske.

Jeg sliter med å se at det kan være noe negativt gjemt inne i meldingen (dere aner ikke hvor mye spindoctoring og gamesmanship det er i meldinger om reimbursement), men aner ikke i hvor stor grad dette er moving the needle for kundene til photocure.

Her er råmaterialet:

Alex · november 5, 2019, 4:46pm

Tolker den som om at sykehusene/klinikkene i enkelte situasjoner vil få mer refusjon/støtte enn tidligere hvis de bruker bruker cysview. Her kan man skille mellom myke scope og harde scope. Men mulig jeg er helt på bærtur. Ikke noe negativt i alle fall.

Rodjer · november 5, 2019, 4:52pm

“from two to
three” procedure codes and increases the reimbursement

I tillegg økt pris såvidt jeg kan se, det må være rimelig oppløftende nyheter.
The increased reimbursement due to the complexity adjustment will be $1,247 ($1,187 in 2019).

Mr.Oncoinvest · november 5, 2019, 4:51pm

«Bladder Neck» er vel ny ser det ut som
52214

sjog · november 5, 2019, 5:17pm

Enkelt forklart:
Refusjon for flere typer behandling
Økning i refundert beløp pr behandling

Savepig · november 5, 2019, 5:28pm

November 2013

Photocure provides update on Medicare reimbursement for Cysview^®
Oslo, Norway, November 28, 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces that the US Centers for Medicare & Medicaid Services (CMS) has released the final rule for the Medicare Outpatient program, which included provisions addressing payments for drugs and procedures for 2014.

Photocure announced on 22 October 2013, in its third quarter 2013 report, that CMS proposed to create a new package payment category to package Cysview® (hexaminolevulinate) into the overall procedure reimbursement code. In the final ruling, CMS confirmed the creation of this new package category for 2014. The rule, which will be effective starting January 2014, will result in reduced payments to hospitals when using Cysview and may compromise patient access to this revolutionary drug.

Juli 2017

UPDATE ON MEDICARE REIMBURSEMENT FOR BLUE LIGHT CYSTOSCOPY WITH CYSVIEW®
Oslo, Norway, July 17, 2017: Photocure ASA (OSE: PHO), announced today that the United States Centers for Medicare & Medicaid Services (CMS) has released the Proposed Rule outlining its 2018 plan to reimburse hospital outpatient departments using Blue Light Cystoscopy (BLCTM) with Cysview®. To Ensure appropriate reimbursement for BLCTM with Cysview, CMS has proposed to create a new set of codes specific to Blue Light Cystoscopy allowing for improved reimbursement for those procedures.

The CMS draft rule for Medicare patients can be accessed at: http://bit.ly/CMS-DRAFT-Rule

“We are greateful that CMS has heard the concerns from stakeholders that the current Medicare reimbursement for Blue Light Cystoscopy procedures involving Cysview® is creating a barrier to patient access to reasonable and necessary care,” stated Kjetil Hestdal, President and CEO of Photocure ASA. “We are pleased that CMS has proposed to improve the reimbursement to hospitals for Blue Light Cystoscopy, and we will submit comments in support of the proposal in the coming weeks,” he noted.

The effectiveness and benefits of Blue Light Cystoscopy (BLCTM) with Cysview® for improved detection and management of bladder cancer have been recognized by leading urology associations including the AUA (American Urological Association), and SUO (Society of Urological Oncology) and patient groups have recognized the potential of using Cysview® as well. In 2016, BLCTM with Cysview® was adopted
into the AUA/SUO Non-Muscle Invasive Bladder Cancer (NMIBC) guidelines.

The comment period for the Proposed Rule closes in early September, and CMS is expected to issue a Final Rule in the fourth quarter of 2017 effective on January 1, 2018.

November 2017:

Photocure ASA:U.S. CMS improves reimbursement for Blue Light Cystoscopy with Cysview®

Oslo, Norway, November 2,2017: Photocure ASA (OSE: PHO), announced today that the United States Centers for Medicare & Medicaid Services (CMS) has issued a Final Rule stating that it will reimburse hospital outpatient departments for certain Blue Light Cystoscopy (BLC™) with Cysview® procedures from January 1, 2018.

“The effectiveness and benefits of using Blue Light Cystoscopy (BLC) with Cysview for improved detection and management of bladder cancer are widely recognized. It is very positive that the CMS have created a separate payment code and additional payment for Blue Light Cystoscopy with Cysviewprocedure as this should result in more patients having access to BLC with Cysviewand should increase equality of care in the management of bladder cancer patients,” said Cheryl Lee, M.D., FACS Chair, Department of Urology, Dorothy M. Davis Chair in Cancer Research at The Ohio State University.

To ensure appropriate reimbursement for BLC with Cysview, CMS has created new and unique codes to describe Blue Light Cystoscopy with the fluorescent imaging agent, Cysview. The CMS final rule for Medicare patients is outlined in the New 2018 CMS hospital outpatient prospective payment system (OPPS) final rule and can be accessed at: http://bit.ly/CMS-Final-Rule

“We are pleased that CMS has implemented new improved coverage and coding for Blue Light Cystoscopy with Cysview procedures. We, along with many stakeholders, including the American Urological Association (AUA), Society of Urological Oncology (SUO), the patient advocacy group Bladder Cancer Advocacy Network, Hospitals and Urologists, have worked hard to secure a reimbursement path for Cysview, in order to ensure better access for Medicare patients to this leading-edge technology for the management of bladder cancer. We estimate the new rule will positively impact approximately 50% of Medicare bladder cancer resection procedures (TURBTs), so this is an important step forward both for patients and our mission to improve the management of bladder cancer,” commented Kjetil Hestdal, President and CEO of Photocure ASA.

The effectiveness and benefits of Blue Light Cystoscopy (BLC) with Cysview for improved detection and management of bladder cancer have been recognized by the AUA/SUO. In 2016, BLC with Cysview was adopted into the AUA/SUO Non-Muscle Invasive Bladder Cancer NMIBC Guidelines.

November 2019

Photocure: Cysview® reimbursement further improved from January 2020
CMS final rule expands complexity adjustment for Hospital Outpatient from two to three procedure codes and increases the reimbursement due to the complexity adjustment for these procedures by $92 compared to 2019.

Oslo, Norway, November 6, 2019 Photocure ASA., (OSE: PHO), The United States Centers for Medicare and Medicaid Services (CMS) has released its Final Rule maintaining the reimbursement code (A Code) for Cysview when used in hospital outpatient and other sites of care and improved the complexity adjustment codes. This will result in additional reimbursement of $92 for certain Blue Light Cystoscopy (BLC™) procedures when used in hospital outpatient departments effective January 1st, 2020.

Link for access to the Rule: https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-24138.pdf

In addition, CMS confirmed that the complexity adjustment will be available for procedures billed under 52204, 52214, and 52224 (52214 being new for 2020), if also billed with the A9589 code for the drug and the C9738 code for the complexity adjustment. The increased reimbursement due to the complexity adjustment will be $1,247 ($1,187 in 2019). This will result in an increase in reimbursement of payment for Blue Light Cystoscopy procedures when used in hospital outpatient department under the complexity adjustment conditions applicable to the three procedures in 2020 from standard white light at $1,771 (for APC 5373) to $3,018 with Cysview (for APC 5374).

“The effectiveness and benefits of using Blue Light Cystoscopy (BLC™) with Cysview for improved detection and management of bladder cancer are widely recognized. We are pleased that CMS has implemented an additional complexity adjustment code for Cysview and improved reimbursement compared to 2019. We, along with many stakeholders in the Bladder Cancer Community, (including the Large Urology Group Practice Association (LUGPA), American Urological Association (AUA), the patient advocacy group Bladder Cancer Advocacy Network (BCAN), and individual Urologists and Patients), will continue to work to further increase access for all patients regardless of the site of care to this leading-edge technology for the management of bladder cancer,” commented Dan Schneider, President and Chief Executive Officer of Photocure ASA.

Ser at siste kommentar i dokumentet er at siste strek er ikke nødvendigvis satt:
"However, we will continue to examine payment for blue light cystoscopy procedures involving Cysview to determine if any changes to this policy would be appropriate in future rulemaking. "